tetano
Editor, Senior Moderator
Antivir Ther
. 2025 Feb;30(1):13596535241313244.
doi: 10.1177/13596535241313244. Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study
Carsten S Larsen[SUP] 1 [/SUP], Caroline L Westergaard[SUP] 2 [/SUP], Nina B Stærke[SUP] 1 [/SUP], Urs Arnet[SUP] 3 [/SUP], Gui Liu[SUP] 4 [/SUP], Line R Kantsø[SUP] 5 [/SUP], Jakob Kjellberg[SUP] 2 [/SUP]
Affiliations
Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics. Outcomes were emergent hospitalization and all-cause mortality during the 28 days after MOV initiation. We estimated the odds ratios (OR) of outcomes by time from positive test to treatment using logistic regression.
Results: We identified 3691 MOV-treated patients, of whom 45.8% were male and mean age was 70.1 years. Most patients (76.2%) initiated MOV within 0-2 days after a positive SARS-CoV-2 test and 16.8% within 3-5 days. Over a 28-day period, rates for all-cause, respiratory- or COVID-19-related, and COVID-19-related hospitalization were 4.8%, 2.6% and 1.5%, respectively. All-cause mortality was 1.6%. Initiation of MOV 3-5 days after a positive SARS-CoV-2 test compared to 1-2 days was associated with an increased risk of all-cause (OR 1.85, 95% CI 1.29-2.67) and respiratory or COVID-19-related (OR 1.78, 95% CI 1.07-2.94) hospitalization, and all-cause mortality (OR 2.90, 95% CI 1.64-5.15).
Conclusion: MOV was primarily prescribed to vaccinated elderly persons with multiple comorbidities. The all-cause hospitalization and mortality rates in this population were low. Early initiation of MOV reduced the risk of hospitalization and death compared with late initiation.
Keywords: COVID-19; SARS-CoV-2; hospitalization; molnupiravir; mortality.
. 2025 Feb;30(1):13596535241313244.
doi: 10.1177/13596535241313244. Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study
Carsten S Larsen[SUP] 1 [/SUP], Caroline L Westergaard[SUP] 2 [/SUP], Nina B Stærke[SUP] 1 [/SUP], Urs Arnet[SUP] 3 [/SUP], Gui Liu[SUP] 4 [/SUP], Line R Kantsø[SUP] 5 [/SUP], Jakob Kjellberg[SUP] 2 [/SUP]
Affiliations
- PMID: 39836400
- DOI: 10.1177/13596535241313244
Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics. Outcomes were emergent hospitalization and all-cause mortality during the 28 days after MOV initiation. We estimated the odds ratios (OR) of outcomes by time from positive test to treatment using logistic regression.
Results: We identified 3691 MOV-treated patients, of whom 45.8% were male and mean age was 70.1 years. Most patients (76.2%) initiated MOV within 0-2 days after a positive SARS-CoV-2 test and 16.8% within 3-5 days. Over a 28-day period, rates for all-cause, respiratory- or COVID-19-related, and COVID-19-related hospitalization were 4.8%, 2.6% and 1.5%, respectively. All-cause mortality was 1.6%. Initiation of MOV 3-5 days after a positive SARS-CoV-2 test compared to 1-2 days was associated with an increased risk of all-cause (OR 1.85, 95% CI 1.29-2.67) and respiratory or COVID-19-related (OR 1.78, 95% CI 1.07-2.94) hospitalization, and all-cause mortality (OR 2.90, 95% CI 1.64-5.15).
Conclusion: MOV was primarily prescribed to vaccinated elderly persons with multiple comorbidities. The all-cause hospitalization and mortality rates in this population were low. Early initiation of MOV reduced the risk of hospitalization and death compared with late initiation.
Keywords: COVID-19; SARS-CoV-2; hospitalization; molnupiravir; mortality.